Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 December 2019
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 December 2019
Cochlear implants for children and adults with severe to profound deafness (TA566)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 March 2019
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 December 2018
Dinutuximab beta for treating neuroblastoma (TA538)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 August 2018
Immunosuppressive therapy for kidney transplant in children and young people (TA482)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 July 2017
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 November 2013
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 November 2013
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2013
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2011
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years (TA213)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 January 2011
Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 May 2010
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years (TA131)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 November 2007
Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) (TA38)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 March 2002
Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 August 2000
Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 July 2021
Secukinumab for treating plaque psoriasis in children and young people [ID1669]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 20 October 2021
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Liraglutide for managing obesity in people aged 12 to 17 [ID1630]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2715]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2716]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC
Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]Status:ProposedProgramme:Technology appraisal guidanceExpected publication date: TBC